ADIAL PHARMACEUTICALS INC (ADIL)
US00688A2050 - Common Stock
ADIAL PHARMACEUTICALS INC
NASDAQ:ADIL (9/13/2024, 8:00:00 PM)
After market: 1.0605 -0.02 (-1.81%)1.08
-0.01 (-0.92%)
Company Profile
Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. The company is headquartered in Charlottesville, Virginia and currently employs 4 full-time employees. The company went IPO on 2018-07-27. The firm is focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. AD04 is investigated in the Company’s ONWARD pivotal Phase III clinical trial for the treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Company’s companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
Company Info
ADIAL PHARMACEUTICALS INC
1180 Seminole Trail, Suite 495
Charlottesville VIRGINIA 22901
P: 14344229800
CEO: William B. Stilley
Employees: 4
Website: https://www.adialpharma.com/
ADIL News
12 days ago - Adial Pharmaceuticals, IncAdial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGLEN ALLEN, Va., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage...
21 days ago - ChartmillDiscover the top movers in Monday's after-hours session and stay informed about the post-market dynamics.The regular session of the US market on Monday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
a month ago - Adial Pharmaceuticals, IncAdial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business UpdateGLEN ALLEN, Va., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage...
a month ago - BusinessInsiderADIL Stock Earnings: Adial Pharmaceuticals Reported Results for Q2 2024InvestorPlace - Stock Market News, Stock Advice & Trading Tips Adial Pharmaceuticals (NASDAQ:ADIL) just reported results for the second quarte...
a month ago - InvestorPlaceADIL Stock Earnings: Adial Pharmaceuticals Reported Results for Q2 2024Adial Pharmaceuticals just reported results for the second quarter of 2024.
a month ago - Adial Pharmaceuticals, IncAdial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04Boudicca will support and advise Adial on its companion diagnostic genetic test to ensure compliance with FDA guidelines...
ADIL Twits
Here you can normally see the latest stock twits on ADIL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
